Effect of hydroxyurea treatment on renal function parameters

Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia

Ofelia Alvarez, Scott T. Miller, Winfred C. Wang, Zhaoyu Luo, M. Beth Mccarville, George J. Schwartz, Bruce Thompson, Thomas Howard, Rathi V. Iyer, Sohail R. Rana, Zora R. Rogers, Sharada A. Sarnaik, Courtney D. Thornburg, Russell E. Ware

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Children with sickle cell anemia (SCA) often develop hyposthenuria and renal hyperfiltration at an early age, possibly contributing to the glomerular injury and renal insufficiency commonly seen later in life. The Phase III randomized double-blinded Clinical Trial of Hydroxyurea in Infants with SCA (BABY HUG) tested the hypothesis that hydroxyurea can prevent kidney dysfunction by reducing hyperfiltration. Procedure: 193 infants with SCA (mean age 13.8 months) received hydroxyurea 20mg/kg/day or placebo for 24 months. 99mTc diethylenetriaminepentaacetic acid (DTPA) clearance, serum creatinine, serum cystatin C, urinalysis, serum and urine osmolality after parent-supervised fluid deprivation, and renal ultrasonography were obtained at baseline and at exit to measure treatment effects on renal function. Results: At exit children treated with hydroxyurea had significantly higher urine osmolality (mean 495mOsm/kg H 2O compared to 452 in the placebo group, P=0.007) and a larger percentage of subjects taking hydroxyurea achieved urine osmolality >500mOsm/kg H 2O. Moreover, children treated with hydroxyurea had smaller renal volumes (P=0.007). DTPA-derived glomerular filtration rate (GFR) was not significantly different between the two treatment groups, but was significantly higher than published norms. GFR estimated by the Chronic Kidney Disease in Children (CKiD) Schwartz formula was the best non-invasive method to estimate GFR in these children, as it was the closest to the DTPA-derived GFR. Conclusion: Treatment with hydroxyurea for 24 months did not influence GFR in young children with SCA. However, hydroxyurea was associated with better urine concentrating ability and less renal enlargement, suggesting some benefit to renal function. (ClinicalTrials.gov number NCT00006400) Pediatr Blood Cancer 2012;59:668-674.

Original languageEnglish (US)
Pages (from-to)668-674
Number of pages7
JournalPediatric Blood and Cancer
Volume59
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Placebos
Clinical Trials
Kidney
Glomerular Filtration Rate
Osmolar Concentration
Urine
Therapeutics
Acids
Kidney Concentrating Ability
Serum
Cystatin C
Urinalysis
Chronic Renal Insufficiency
Renal Insufficiency
Ultrasonography
Creatinine
Wounds and Injuries

Keywords

  • Glomerular filtration rate
  • Hydroxyurea
  • Kidney function
  • Urine osmolality

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Effect of hydroxyurea treatment on renal function parameters : Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. / Alvarez, Ofelia; Miller, Scott T.; Wang, Winfred C.; Luo, Zhaoyu; Mccarville, M. Beth; Schwartz, George J.; Thompson, Bruce; Howard, Thomas; Iyer, Rathi V.; Rana, Sohail R.; Rogers, Zora R.; Sarnaik, Sharada A.; Thornburg, Courtney D.; Ware, Russell E.

In: Pediatric Blood and Cancer, Vol. 59, No. 4, 10.2012, p. 668-674.

Research output: Contribution to journalArticle

Alvarez, O, Miller, ST, Wang, WC, Luo, Z, Mccarville, MB, Schwartz, GJ, Thompson, B, Howard, T, Iyer, RV, Rana, SR, Rogers, ZR, Sarnaik, SA, Thornburg, CD & Ware, RE 2012, 'Effect of hydroxyurea treatment on renal function parameters: Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia', Pediatric Blood and Cancer, vol. 59, no. 4, pp. 668-674. https://doi.org/10.1002/pbc.24100
Alvarez, Ofelia ; Miller, Scott T. ; Wang, Winfred C. ; Luo, Zhaoyu ; Mccarville, M. Beth ; Schwartz, George J. ; Thompson, Bruce ; Howard, Thomas ; Iyer, Rathi V. ; Rana, Sohail R. ; Rogers, Zora R. ; Sarnaik, Sharada A. ; Thornburg, Courtney D. ; Ware, Russell E. / Effect of hydroxyurea treatment on renal function parameters : Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 4. pp. 668-674.
@article{8e19431d11cc42d8836051e49ddd65ca,
title = "Effect of hydroxyurea treatment on renal function parameters: Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia",
abstract = "Background: Children with sickle cell anemia (SCA) often develop hyposthenuria and renal hyperfiltration at an early age, possibly contributing to the glomerular injury and renal insufficiency commonly seen later in life. The Phase III randomized double-blinded Clinical Trial of Hydroxyurea in Infants with SCA (BABY HUG) tested the hypothesis that hydroxyurea can prevent kidney dysfunction by reducing hyperfiltration. Procedure: 193 infants with SCA (mean age 13.8 months) received hydroxyurea 20mg/kg/day or placebo for 24 months. 99mTc diethylenetriaminepentaacetic acid (DTPA) clearance, serum creatinine, serum cystatin C, urinalysis, serum and urine osmolality after parent-supervised fluid deprivation, and renal ultrasonography were obtained at baseline and at exit to measure treatment effects on renal function. Results: At exit children treated with hydroxyurea had significantly higher urine osmolality (mean 495mOsm/kg H 2O compared to 452 in the placebo group, P=0.007) and a larger percentage of subjects taking hydroxyurea achieved urine osmolality >500mOsm/kg H 2O. Moreover, children treated with hydroxyurea had smaller renal volumes (P=0.007). DTPA-derived glomerular filtration rate (GFR) was not significantly different between the two treatment groups, but was significantly higher than published norms. GFR estimated by the Chronic Kidney Disease in Children (CKiD) Schwartz formula was the best non-invasive method to estimate GFR in these children, as it was the closest to the DTPA-derived GFR. Conclusion: Treatment with hydroxyurea for 24 months did not influence GFR in young children with SCA. However, hydroxyurea was associated with better urine concentrating ability and less renal enlargement, suggesting some benefit to renal function. (ClinicalTrials.gov number NCT00006400) Pediatr Blood Cancer 2012;59:668-674.",
keywords = "Glomerular filtration rate, Hydroxyurea, Kidney function, Urine osmolality",
author = "Ofelia Alvarez and Miller, {Scott T.} and Wang, {Winfred C.} and Zhaoyu Luo and Mccarville, {M. Beth} and Schwartz, {George J.} and Bruce Thompson and Thomas Howard and Iyer, {Rathi V.} and Rana, {Sohail R.} and Rogers, {Zora R.} and Sarnaik, {Sharada A.} and Thornburg, {Courtney D.} and Ware, {Russell E.}",
year = "2012",
month = "10",
doi = "10.1002/pbc.24100",
language = "English (US)",
volume = "59",
pages = "668--674",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of hydroxyurea treatment on renal function parameters

T2 - Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia

AU - Alvarez, Ofelia

AU - Miller, Scott T.

AU - Wang, Winfred C.

AU - Luo, Zhaoyu

AU - Mccarville, M. Beth

AU - Schwartz, George J.

AU - Thompson, Bruce

AU - Howard, Thomas

AU - Iyer, Rathi V.

AU - Rana, Sohail R.

AU - Rogers, Zora R.

AU - Sarnaik, Sharada A.

AU - Thornburg, Courtney D.

AU - Ware, Russell E.

PY - 2012/10

Y1 - 2012/10

N2 - Background: Children with sickle cell anemia (SCA) often develop hyposthenuria and renal hyperfiltration at an early age, possibly contributing to the glomerular injury and renal insufficiency commonly seen later in life. The Phase III randomized double-blinded Clinical Trial of Hydroxyurea in Infants with SCA (BABY HUG) tested the hypothesis that hydroxyurea can prevent kidney dysfunction by reducing hyperfiltration. Procedure: 193 infants with SCA (mean age 13.8 months) received hydroxyurea 20mg/kg/day or placebo for 24 months. 99mTc diethylenetriaminepentaacetic acid (DTPA) clearance, serum creatinine, serum cystatin C, urinalysis, serum and urine osmolality after parent-supervised fluid deprivation, and renal ultrasonography were obtained at baseline and at exit to measure treatment effects on renal function. Results: At exit children treated with hydroxyurea had significantly higher urine osmolality (mean 495mOsm/kg H 2O compared to 452 in the placebo group, P=0.007) and a larger percentage of subjects taking hydroxyurea achieved urine osmolality >500mOsm/kg H 2O. Moreover, children treated with hydroxyurea had smaller renal volumes (P=0.007). DTPA-derived glomerular filtration rate (GFR) was not significantly different between the two treatment groups, but was significantly higher than published norms. GFR estimated by the Chronic Kidney Disease in Children (CKiD) Schwartz formula was the best non-invasive method to estimate GFR in these children, as it was the closest to the DTPA-derived GFR. Conclusion: Treatment with hydroxyurea for 24 months did not influence GFR in young children with SCA. However, hydroxyurea was associated with better urine concentrating ability and less renal enlargement, suggesting some benefit to renal function. (ClinicalTrials.gov number NCT00006400) Pediatr Blood Cancer 2012;59:668-674.

AB - Background: Children with sickle cell anemia (SCA) often develop hyposthenuria and renal hyperfiltration at an early age, possibly contributing to the glomerular injury and renal insufficiency commonly seen later in life. The Phase III randomized double-blinded Clinical Trial of Hydroxyurea in Infants with SCA (BABY HUG) tested the hypothesis that hydroxyurea can prevent kidney dysfunction by reducing hyperfiltration. Procedure: 193 infants with SCA (mean age 13.8 months) received hydroxyurea 20mg/kg/day or placebo for 24 months. 99mTc diethylenetriaminepentaacetic acid (DTPA) clearance, serum creatinine, serum cystatin C, urinalysis, serum and urine osmolality after parent-supervised fluid deprivation, and renal ultrasonography were obtained at baseline and at exit to measure treatment effects on renal function. Results: At exit children treated with hydroxyurea had significantly higher urine osmolality (mean 495mOsm/kg H 2O compared to 452 in the placebo group, P=0.007) and a larger percentage of subjects taking hydroxyurea achieved urine osmolality >500mOsm/kg H 2O. Moreover, children treated with hydroxyurea had smaller renal volumes (P=0.007). DTPA-derived glomerular filtration rate (GFR) was not significantly different between the two treatment groups, but was significantly higher than published norms. GFR estimated by the Chronic Kidney Disease in Children (CKiD) Schwartz formula was the best non-invasive method to estimate GFR in these children, as it was the closest to the DTPA-derived GFR. Conclusion: Treatment with hydroxyurea for 24 months did not influence GFR in young children with SCA. However, hydroxyurea was associated with better urine concentrating ability and less renal enlargement, suggesting some benefit to renal function. (ClinicalTrials.gov number NCT00006400) Pediatr Blood Cancer 2012;59:668-674.

KW - Glomerular filtration rate

KW - Hydroxyurea

KW - Kidney function

KW - Urine osmolality

UR - http://www.scopus.com/inward/record.url?scp=84864917063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864917063&partnerID=8YFLogxK

U2 - 10.1002/pbc.24100

DO - 10.1002/pbc.24100

M3 - Article

VL - 59

SP - 668

EP - 674

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -